For the latest FDA MedWatch alerts, July 16, 2019 -- Altaire Pharmaceuticals, Inc., announces today that it is voluntarily recalling the Prescription (RX) and Over-the-Counter (OTC) drug products and lots, within expiry, sold by OCuSOFT during the time period as indicated in the tables below. Any questions regarding this VOLUNTARY RECALL to the RETAIL LEVEL can be directed to Altaire Pharmaceuticals Inc., by calling 1-800-258-2471, or e-mailing otcdruggist@aol.com Monday thru Friday from 8:30 a.m. to 5:00 p.m. Available for Android and iOS devices. For the latest FDA MedWatch alerts, July 15, 2019 -- Altaire Pharmaceuticals, Inc., announces today that it is voluntarily recalling the over the counter (OTC) and prescription (Rx) drug products and lots, within expiry, it has manufactured and distributed under the Altaire label and trade dress during the time period as indicated below. Administration of a non-sterile product intended to be sterile may result in serious and potentially life-threatening infections or death.This recall is being carried out to the RETAIL LEVEL and IS ONLY FOR THE SPECIFIC LOTS LISTED BELOW. Altaire ships the products labeled for OCuSOFT only to OCuSOFT. Altaire has notified OCuSOFT by e-mail on July 15, 2019 announcing the recalls of the products/lots identified herein, with specific directions for return of all units of the impacted lots. Altaire has also requested that OCuSOFT perform a subrecall.Altaire has notified OCuSOFT by e-mail on July 15, 2019 announcing the recalls of the products/lots identified herein, with specific directions for return of all units of the impacted lots.Any questions regarding this VOLUNTARY RECALL to the RETAIL LEVEL can be directed to Altaire Pharmaceuticals Inc., by calling 1-800-258-2471, or e-mailing Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.Altaire takes its mission of customer safety and providing quality products very seriously. Following is a list of possible medication recalls, market withdrawals, alerts and warnings. A Retail Level recall is limited to product lots currently in inventory on hand at any distributor to which Altaire Pharmaceuticals, Inc. has sold these products.TO DATE, ALTAIRE HAS NOT OBTAINED ANY OUT OF SPECIFICATION RESULTS, INCLUDING IN-HOUSE AND THIRD-PARTY STERILITY TESTING, FOR THESE PRODUCTS.The foregoing products are manufactured and labeled by Altaire Pharmaceuticals, Inc. Altaire has notified all distributors by e-mail on July 15, 2019 announcing the recalls of the products/lots identified herein, with specific directions for return of all units of the impacted lots. As a precautionary measure, Altaire is voluntarily initiating this recall due to management concerns regarding the sufficiency of Quality Assurance controls over critical systems in the manufacturing facility. No other lots are being recalled. These announcements (with one exception due to what we believe to be an FDA error) are all listed on the FDA’s “recalls, market withdrawals and safety alerts” website. The company is committed to, and diligently working to, ensure the sufficiency of Quality Assurance controls over critical systems in its manufacturing facility.Gavreto (pralsetinib) is an oral selective RET kinase inhibitor for the...Onureg (azacitidine) is a nucleoside metabolic inhibitor indicated for the...Qdolo (tramadol hydrochloride) is an opioid agonist indicated in adults for ...Xaracoll (bupivacaine hydrochloride) is a fully bioresorbable collagen implant...The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records.